NasdaqGS - Nasdaq Real Time Price USD

TherapeuticsMD, Inc. (TXMD)

Compare
1.6000 -0.0200 (-1.23%)
As of 2:52 PM EDT. Market Open.
Loading Chart for TXMD
DELL
  • Previous Close 1.6200
  • Open 1.6000
  • Bid 1.3600 x 100
  • Ask 1.8700 x 100
  • Day's Range 1.5900 - 1.6500
  • 52 Week Range 1.4300 - 3.0700
  • Volume 9,270
  • Avg. Volume 14,265
  • Market Cap (intraday) 18.452M
  • Beta (5Y Monthly) 1.13
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4300
  • Earnings Date Nov 12, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

www.therapeuticsmd.com

1

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TXMD

View More

Performance Overview: TXMD

Trailing total returns as of 10/7/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TXMD
28.89%
S&P 500
19.43%

1-Year Return

TXMD
43.86%
S&P 500
32.21%

3-Year Return

TXMD
95.43%
S&P 500
30.55%

5-Year Return

TXMD
99.10%
S&P 500
92.97%

Compare To: TXMD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TXMD

View More

Valuation Measures

Annual
As of 10/4/2024
  • Market Cap

    18.94M

  • Enterprise Value

    21.30M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    18.49

  • Price/Book (mrq)

    0.68

  • Enterprise Value/Revenue

    21.39

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -7.60%

  • Return on Equity (ttm)

    -16.42%

  • Revenue (ttm)

    996k

  • Net Income Avi to Common (ttm)

    -4.83M

  • Diluted EPS (ttm)

    -0.4300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.23M

  • Total Debt/Equity (mrq)

    27.44%

  • Levered Free Cash Flow (ttm)

    -12.13M

Research Analysis: TXMD

View More

Company Insights: TXMD

Research Reports: TXMD

View More

People Also Watch